If you like this story please SHARE!

GW Pharma's Cannabis-Derived Drug Shows Promise in Brain Cancer Study

British-based GW Pharmaceuticals​ received more good news regarding its cannabis-based drug development efforts. The drug-maker published positive Phase 2 data from an exploratory placebo-controlled study testing a combination treatment of active cannabis ingredients tetrahydrocannabinol and cannabidiol (THC: CBD) on 21 patients diagnosed with an aggressive brain tumor called recurrent glioblastoma multiforme (GBM). GW started the study with an initial safety phase so the investigators could gage the safety of THC: CBD in conjunction with dose-intense temozolomide, which is used as the standard first-line treatment for GMB. Next, the team moved into the randomized placebo-controlled phase where 12 patients received THC: CBD as an add-on therapy whereas the remainder were administered the placebo with the standard of care. Results from this study had shown patients with documented recurrent treatment getting treated with THC: CBD saw an 83 percent one year survival rate versus 53 percent for those receiving placebo. “The findings from this well-designed controlled study suggest that the addition of a combination of THC and CBD to patients on dose-intensive temozolomide produced relevant improvements in survival compared with placebo an